Bookmark and Share
N-alpha-(2-carboxyl)benzoyl-N5-(2-chloro-1-iminoethyl)ornithine amide (CID 54756940) - Compound BioActivity Data
.
BioActivity Outcomes:
Active(21)
 
 
Inactive(4)
 
 
Unspecified(19)
 
 
Top Targets:
PAD(2)
 
 
BioAssay Types:
Literature(44)
 
 
 
 
BioActivity Types:
IC50(8)
 
 
Data download

Chemical Probe    Active    Inactive    Inconclusive    Unspecified   

Total Bioassays: 44    Data Row: 44   Total Pages: 1   
Sort: [Click the result table header to sort]
#SubstanceActivityBioAssayTargetLinks
OutcomeTypeValue [μM]
1
[SID136924156]
IC50 0.69Irreversible inhibition of PAD3 assessed as hydrolysis of benzoyl-L-arginine ethyl ester preincubated for 15 mins measured after 15 mins by fluorometric analysis [AID627374, Type: Literature]
View
2
[SID136924156]
IC50 0.84Irreversible inhibition of PAD1 assessed as hydrolysis of benzoyl-L-arginine ethyl ester preincubated for 15 mins measured after 15 mins by fluorometric analysis [AID627372, Type: Literature]
View
3
[SID136924156]
IC50 1.1Irreversible inhibition of PAD4 Q346A mutant assessed as hydrolysis of benzoyl-L-arginine ethyl ester preincubated for 15 mins measured after 15 mins [AID627438, Type: Literature]
View
4
[SID136924156]
IC50 2.2Irreversible inhibition of PAD4 assessed as hydrolysis of benzoyl-L-arginine ethyl ester preincubated for 15 mins measured after 15 mins by fluorometric analysis [AID627371, Type: Literature]
View
5
[SID136924156]
IC50 2.4Irreversible inhibition of PAD4 Q346E mutant assessed as hydrolysis of benzoyl-L-arginine ethyl ester preincubated for 15 mins measured after 15 mins [AID627437, Type: Literature]
View
6
[SID136924156]
IC50 5.3Irreversible inhibition of PAD4 R374K mutant assessed as hydrolysis of benzoyl-L-arginine ethyl ester preincubated for 15 mins measured after 15 mins [AID627439, Type: Literature]
View
7
[SID136924156]
IC50 6.2Irreversible inhibition of PAD2 assessed as hydrolysis of benzoyl-L-arginine ethyl ester preincubated for 15 mins measured after 15 mins by fluorometric analysis [AID627373, Type: Literature]
View
8
[SID136924156]
IC50 22Irreversible inhibition of PAD4 R374A mutant assessed as hydrolysis of benzoyl-L-arginine ethyl ester preincubated for 15 mins measured after 15 mins [AID627440, Type: Literature]
View
9
[SID136924156]
Irreversible inhibition of PAD1 assessed as citrulline formation at 1 mM measured after 20 hrs by colorimetric assay in presence of 2 mM benzoyl-L-arginine ethyl ester [AID626681, Type: Literature]
View
10
[SID136924156]
Irreversible inhibition of PAD1 assessed as residual activity at 1 mM measured after 20 hrs by colorimetric assay [AID627375, Type: Literature]
View
11
[SID136924156]
Irreversible inhibition of PAD2 assessed as residual activity at 1 mM measured after 20 hrs by colorimetric assay in presence of 2 mM benzoyl-L-arginine ethyl ester [AID626722, Type: Literature]
View
12
[SID136924156]
Irreversible inhibition of PAD3 assessed as residual activity at 1 mM measured after 20 hrs by colorimetric assay in presence of 2 mM benzoyl-L-arginine ethyl ester [AID626723, Type: Literature]
View
13
[SID136924156]
Irreversible inhibition of PAD4 assessed as residual activity at 1 mM measured after 20 hrs by colorimetric assay in presence of 2 mM benzoyl-L-arginine ethyl ester [AID626724, Type: Literature]
View
14
[SID136924156]
Irreversible inhibition of PAD2 assessed as residual activity at 1 mM measured after 20 hrs by colorimetric assay [AID627426, Type: Literature]
View
15
[SID136924156]
Irreversible inhibition of PAD3 assessed as residual activity at 1 mM measured after 20 hrs by colorimetric assay [AID627427, Type: Literature]
View
16
[SID136924156]
Irreversible inhibition of PAD4 assessed as residual activity at 1 mM measured after 20 hrs by colorimetric assay [AID627428, Type: Literature]
View
17
[SID136924156]
Inhibition of PAD4 in calcium ionophore A23187 stimulated-human HL60 granulocytes assessed as reduction in deaminated histone H3 at 1 uM after 30 mins by Western blotting [AID627442, Type: Literature]Protein-arginine deiminase type-4 [gi:296439260]
View
18
[SID136924156]
Inhibition of PAD4 in calcium ionophore A23187 stimulated-human HL60 granulocytes assessed as reduction in deaminated histone H3 at 100 uM after 48 hrs by Western blotting [AID627443, Type: Literature]Protein-arginine deiminase type-4 [gi:296439260]
View
19
[SID136924156]
Induction of human HL60 cell differentiation assessed as increase in PAD4 expression level at 10 uM after 6 hrs by Western blotting [AID627446, Type: Literature]
View
20
[SID136924156]
Induction of human HL60 cell differentiation assessed as increase in PAD4 expression level at 1 uM after 12 hrs by Western blotting [AID627447, Type: Literature]
View
21
[SID136924156]
Induction of human HL60 cell differentiation assessed as increase in PAD4 expression level at 1 uM after 24 hrs by Western blotting [AID627448, Type: Literature]
View
22
[SID136924156]
Ratio of Kinact to Ki for PAD2 [AID627434, Type: Literature]
View
23
[SID136924156]
Ratio of Kinact to Ki for PAD3 [AID627435, Type: Literature]
View
24
[SID136924156]
Ratio of Kinact to Ki for PAD4 [AID627436, Type: Literature]
View
25
[SID136924156]
Induction of human HL60 cell differentiation assessed as increase in PAD4 expression level after 24 hrs by Western blotting [AID626672, Type: Literature]
View
26
[SID136924156]
Induction of human HL60 cell differentiation assessed as increase in PAD4 expression level at 1 to 10 uM by Western blotting [AID626673, Type: Literature]
View
27
[SID136924156]
Ratio of Kcat to Km for PAD4 Q346A mutant [AID626677, Type: Literature]
View
28
[SID136924156]
Ratio of Kcat to Km for PAD4 R347K mutant [AID626678, Type: Literature]
View
29
[SID136924156]
Ratio of Kcat to Km for PAD4 R347A mutant [AID626679, Type: Literature]
View
30
[SID136924156]
Irreversible inhibition of PAD3 assessed as residual activity measured after 20 hrs by colorimetric assay [AID627431, Type: Literature]
View
31
[SID136924156]
Irreversible inhibition of PAD4 assessed as residual activity measured after 20 hrs by colorimetric assay [AID627432, Type: Literature]
View
32
[SID136924156]
Ratio of Kinact to Ki for PAD1 [AID627433, Type: Literature]
View
33
[SID136924156]
Ratio of Kinact to Ki for Cl-amidine to compound for PAD4 [AID626738, Type: Literature]
View
34
[SID136924156]
Selectivity ratio of PAD1 over PAD2 [AID626729, Type: Literature]
View
35
[SID136924156]
Selectivity ratio of PAD1 over PAD3 [AID626730, Type: Literature]
View
36
[SID136924156]
Selectivity ratio of PAD1 over PAD4 [AID626731, Type: Literature]
View
37
[SID136924156]
Ratio of Kinact to Ki for Cl-amidine to compound for PAD1 [AID626736, Type: Literature]
View
38
[SID136924156]
Ratio of Kinact to Ki for Cl-amidine to compound for PAD2 [AID626737, Type: Literature]
View
39
[SID136924156]
Ratio of Kcat to Km for PAD4 Q346E mutant [AID627441, Type: Literature]
View
40
[SID136924156]
Potentiation of doxorubicin-induced cytotoxicity against human HL60 cells assessed as reduction in cell viability at 100 nM after 24 hrs by MTT assay relative to control [AID627445, Type: Literature]
View
41
[SID136924156]
Irreversible inhibition of PAD4 assessed as residual activity at 1 mM measured after 20 hrs by colorimetric assay in presence of 10 mM benzoyl-L-arginine ethyl ester [AID626728, Type: Literature]
View
42
[SID136924156]
Irreversible inhibition of PAD1 assessed as citrulline formation at 1 mM measured after 20 hrs by colorimetric assay in presence of 10 mM benzoyl-L-arginine ethyl ester [AID626725, Type: Literature]
View
43
[SID136924156]
Irreversible inhibition of PAD2 assessed as residual activity at 1 mM measured after 20 hrs by colorimetric assay in presence of 10 mM benzoyl-L-arginine ethyl ester [AID626726, Type: Literature]
View
44
[SID136924156]
Irreversible inhibition of PAD3 assessed as residual activity at 1 mM measured after 20 hrs by colorimetric assay in presence of 10 mM benzoyl-L-arginine ethyl ester [AID626727, Type: Literature]
View